Carnosic acid enhances cisplatin sensitivity and suppresses gastric cancer progression via the TP53/SLC7A11/ALOX12 axis

Abstract Background Gastric cancer (GC) remains a significant global health challenge due to its high mortality and frequent resistance to chemotherapy drugs like cisplatin (DDP). Carnosic acid (CA), a phenolic diterpene, exhibits potential anti-cancer properties. This study aimed to investigate the...

Full description

Saved in:
Bibliographic Details
Main Authors: Li Zhou, Bin Xu, Baojian Li
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Hereditas
Subjects:
Online Access:https://doi.org/10.1186/s41065-025-00508-2
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849235085018005504
author Li Zhou
Bin Xu
Baojian Li
author_facet Li Zhou
Bin Xu
Baojian Li
author_sort Li Zhou
collection DOAJ
description Abstract Background Gastric cancer (GC) remains a significant global health challenge due to its high mortality and frequent resistance to chemotherapy drugs like cisplatin (DDP). Carnosic acid (CA), a phenolic diterpene, exhibits potential anti-cancer properties. This study aimed to investigate the role of CA in regulating GC development and DDP sensitivity. Methods The half-maximal inhibitory concentration (IC50) of DDP and cell viability were determined using a cell counting kit-8 assay. Cell proliferation was evaluated by a 5-Ethynyl-2’-deoxyuridine assay, while cell migration was assessed by a transwell assay. Cell death was analyzed through flow cytometry, fluorometric assay, and colorimetric assays. The targets of CA were identified using network pharmacology. Western blotting was employed to detect the protein expression of tumor protein p53 (TP53), solute carrier family 7 member 11 (SLC7A11), and arachidonate 12-lipoxygenase, 12 S type (ALOX12). Results CA treatment significantly inhibited GC cell proliferation and migration and enhanced cell death. The treatment also elevated reactive oxygen species (ROS) and Fe2+ levels, while reducing glutathione (GSH) levels and the IC50 value for DDP in GC cells. In addition, TP53 was identified as a target of CA, and its protein expression was upregulated by CA treatment in GC cells. Silencing TP53 attenuated the effects of CA on cell proliferation, migration, death, and the sensitivity of tumor cells to DDP. Further, CA regulated the TP53-mediated SLC7A11/ALOX12 pathway. Conclusion CA improved the sensitivity of GC cells to DDP and inhibited their malignant progression by regulating the TP53-mediated SLC7A11/ALOX12 axis, highlighting its potential clinical significance for GC treatment.
format Article
id doaj-art-6e14fec17cd044378d8d9050d774a4f4
institution Kabale University
issn 1601-5223
language English
publishDate 2025-07-01
publisher BMC
record_format Article
series Hereditas
spelling doaj-art-6e14fec17cd044378d8d9050d774a4f42025-08-20T04:02:55ZengBMCHereditas1601-52232025-07-01162111010.1186/s41065-025-00508-2Carnosic acid enhances cisplatin sensitivity and suppresses gastric cancer progression via the TP53/SLC7A11/ALOX12 axisLi Zhou0Bin Xu1Baojian Li2Department of Traditional Chinese Medicine, Changzhou Fourth People’s HospitalDepartment of Traditional Chinese Medicine, Changzhou Fourth People’s HospitalDepartment of Pharmacy, The Fourth People’s Hospital of ChangzhouAbstract Background Gastric cancer (GC) remains a significant global health challenge due to its high mortality and frequent resistance to chemotherapy drugs like cisplatin (DDP). Carnosic acid (CA), a phenolic diterpene, exhibits potential anti-cancer properties. This study aimed to investigate the role of CA in regulating GC development and DDP sensitivity. Methods The half-maximal inhibitory concentration (IC50) of DDP and cell viability were determined using a cell counting kit-8 assay. Cell proliferation was evaluated by a 5-Ethynyl-2’-deoxyuridine assay, while cell migration was assessed by a transwell assay. Cell death was analyzed through flow cytometry, fluorometric assay, and colorimetric assays. The targets of CA were identified using network pharmacology. Western blotting was employed to detect the protein expression of tumor protein p53 (TP53), solute carrier family 7 member 11 (SLC7A11), and arachidonate 12-lipoxygenase, 12 S type (ALOX12). Results CA treatment significantly inhibited GC cell proliferation and migration and enhanced cell death. The treatment also elevated reactive oxygen species (ROS) and Fe2+ levels, while reducing glutathione (GSH) levels and the IC50 value for DDP in GC cells. In addition, TP53 was identified as a target of CA, and its protein expression was upregulated by CA treatment in GC cells. Silencing TP53 attenuated the effects of CA on cell proliferation, migration, death, and the sensitivity of tumor cells to DDP. Further, CA regulated the TP53-mediated SLC7A11/ALOX12 pathway. Conclusion CA improved the sensitivity of GC cells to DDP and inhibited their malignant progression by regulating the TP53-mediated SLC7A11/ALOX12 axis, highlighting its potential clinical significance for GC treatment.https://doi.org/10.1186/s41065-025-00508-2Carnosic acidGastric cancerCisplatinTP53
spellingShingle Li Zhou
Bin Xu
Baojian Li
Carnosic acid enhances cisplatin sensitivity and suppresses gastric cancer progression via the TP53/SLC7A11/ALOX12 axis
Hereditas
Carnosic acid
Gastric cancer
Cisplatin
TP53
title Carnosic acid enhances cisplatin sensitivity and suppresses gastric cancer progression via the TP53/SLC7A11/ALOX12 axis
title_full Carnosic acid enhances cisplatin sensitivity and suppresses gastric cancer progression via the TP53/SLC7A11/ALOX12 axis
title_fullStr Carnosic acid enhances cisplatin sensitivity and suppresses gastric cancer progression via the TP53/SLC7A11/ALOX12 axis
title_full_unstemmed Carnosic acid enhances cisplatin sensitivity and suppresses gastric cancer progression via the TP53/SLC7A11/ALOX12 axis
title_short Carnosic acid enhances cisplatin sensitivity and suppresses gastric cancer progression via the TP53/SLC7A11/ALOX12 axis
title_sort carnosic acid enhances cisplatin sensitivity and suppresses gastric cancer progression via the tp53 slc7a11 alox12 axis
topic Carnosic acid
Gastric cancer
Cisplatin
TP53
url https://doi.org/10.1186/s41065-025-00508-2
work_keys_str_mv AT lizhou carnosicacidenhancescisplatinsensitivityandsuppressesgastriccancerprogressionviathetp53slc7a11alox12axis
AT binxu carnosicacidenhancescisplatinsensitivityandsuppressesgastriccancerprogressionviathetp53slc7a11alox12axis
AT baojianli carnosicacidenhancescisplatinsensitivityandsuppressesgastriccancerprogressionviathetp53slc7a11alox12axis